A structured literature review of interventions used in the management of nonalcoholic steatohepatitis ( NASH )-Reference-Cited by-同舟云学术

A structured literature review of interventions used in the management of nonalcoholic steatohepatitis ( NASH )

Published:2019-05-27 Issue:3 Volume:7 Page:e00485
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Povsic Manca¹^ORCID,Oliver Louisa¹,Jiandani Neha Raju¹,Perry Richard¹^ORCID,Bottomley Juliana²

Affiliation:

1. Adelphi Values Bollington Cheshire UK

2. Gilead Sciences Inc. Uxbridge Middlesex UK

Funder

Gilead Sciences

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.485

Reference76 articles.

1. European Medicines Agency.Reflection paper on regulatory requirements for the development of medicinal products for chronic non‐infections liver disease (PBC PSC NASH).2018;https://www.ema.europa.eu/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-chronic-non-infectious-liver_en.pdfAccessed 26th November 2018.

2. Non-alcoholic fatty liver disease: An expanded review

3. Nonalcoholic steatohepatitis: clinical presentation, diagnosis, and treatment;Stengel JZ;Gastroenterol Hepatol,2006

4. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

5. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MASLD- Global prevalence, pathophysiological processes and management pathways- tackling a complex problem;Gastroenterology & Hepatology: Open access;2024-07-25

2. Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis;Annals of Medicine & Surgery;2024-05-22

3. A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis;Nature Communications;2023-11-06

4. Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions;Cureus;2023-08-02

5. Hepatic Pin1 Expression, Particularly in Nuclei, Is Increased in NASH Patients in Accordance with Evidence of the Role of Pin1 in Lipid Accumulation Shown in Hepatoma Cell Lines;International Journal of Molecular Sciences;2023-05-16